MultiCell Technologies Inc (MCET)

[Semperfifi]

http://livercancerconnect.org/drug-watch

Updated March 1, 2014

MCT 485 has entered preclinical trials

SGI-110 Switches on tumor-suppressor genes Astex Pharmaceuticals, Dublin, CA

Phase II
TKM-PLK1 miRNA inhibitor of protein that promotes tumor growth Tekmira Pharma, Burnaby, B.C., Canada

Phase I/II
ALN-VSP02 Switches off tumor growth genes Alnylam, Cambridge, MA

Phase I
MRX34(Tumor suppressor microRNA) Switches off tumor growth genes Mirna Therapeutics,
Austin, TX Phase I
Chol-anti-miR-221 Blocks cancer-causing genes Ohio State University, Columbus, OH Preclinical
MCT-485 Kills tumor cells and stimulates immune system MultiCell Technologies, Woonsocket, RI Preclinical